Alaunos Therapeutics, Inc.
TCRT
$1.48
-$0.02-1.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | -- | -90.91% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00% | -- | -90.91% | -- |
| Cost of Revenue | -96.09% | -96.53% | -98.06% | -69.97% | -53.68% |
| Gross Profit | 96.09% | 96.60% | 98.08% | 69.90% | 26.62% |
| SG&A Expenses | -71.86% | -67.49% | -48.96% | -16.99% | 9.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -84.10% | -85.79% | -81.98% | -44.28% | -35.27% |
| Operating Income | 84.10% | 85.83% | 81.99% | 44.20% | 12.46% |
| Income Before Tax | 86.70% | 87.13% | 83.26% | 14.37% | 4.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.70% | 87.13% | 83.26% | 14.37% | 4.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.70% | 87.13% | 83.26% | 14.37% | 4.24% |
| EBIT | 84.10% | 85.83% | 81.99% | 44.20% | 12.46% |
| EBITDA | 82.46% | 84.52% | 80.61% | 41.45% | 13.44% |
| EPS Basic | 86.71% | 87.15% | 83.30% | 20.35% | 14.19% |
| Normalized Basic EPS | 84.01% | 87.50% | 83.30% | 54.55% | 28.67% |
| EPS Diluted | 86.71% | 87.15% | 83.30% | 16.66% | 14.19% |
| Normalized Diluted EPS | 84.01% | 87.50% | 83.30% | 54.55% | 28.67% |
| Average Basic Shares Outstanding | 0.06% | 0.16% | 0.21% | 7.51% | 11.60% |
| Average Diluted Shares Outstanding | 0.06% | 0.16% | 0.21% | 7.51% | 11.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
